1365-2133/asset/cover.gif?v=1&s=413074e1e506a67a21dcc4e2de9ff9b6ce256d16 "British Journal of Dermatology")
Funding sources None.
1365-2133/asset/olbannerleft.jpg?v=1&s=3d13800721e0d35da4d49e694f63a9d81054ca17)
1365-2133/asset/olbannerright.jpg?v=1&s=9ea9b247f2d7101244b2bef959a0874a886ec363)
REVIEW ARTICLE
Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials
Article first published online: 7 SEP 2012
DOI: 10.1111/j.1365-2133.2012.11061.x
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
Additional Information
How to Cite
Roozeboom, M.H., Arits, A.H.H.M., Nelemans, P.J. and Kelleners-Smeets, N.W.J. (2012), Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. British Journal of Dermatology, 167: 733–756. doi: 10.1111/j.1365-2133.2012.11061.x
Conflicts of interest None declared.
Publication History
- Issue published online: 26 SEP 2012
- Article first published online: 7 SEP 2012
- Accepted manuscript online: 21 MAY 2012 08:19AM EST
- Accepted for publication 13 May 2012
- Abstract
- Article
- References
- Cited By
Summary
Background Several noninvasive treatment modalities are available for superficial basal cell carcinoma (sBCC).
Objectives This systematic review aims to determine residue, recurrence and tumour-free survival probabilities of patients with primary sBCC treated with the currently most frequently used therapies.
Methods The PubMed (January 1946 to October 2010), EMBASE (January 1989 to October 2010) and Cochrane (January 1993 to October 2010) databases, and reference lists were searched without date restriction. Inclusion criteria were studies that included primary, histologically proven sBCCs, that reported on residue and/or recurrence probabilities after treatment, and had a minimum follow-up period of 12 weeks. Both randomized and nonrandomized studies were included. The primary and secondary outcomes were the probability of complete response and tumour-free survival, respectively. Two independent reviewers selected 36 studies (14 randomized and 22 nonrandomized), and extracted residue, cumulative recurrence and tumour-free survival probabilities.
Results Pooled estimates of percentages of sBCC with complete response at 12 weeks post-treatment, derived from 28 studies, were 86·2% [95% confidence interval (CI) 82–90%] for imiquimod treatment, and 79·0% (95% CI 71–87%) for photodynamic therapy (PDT). With respect to tumour-free survival at 1 year, the pooled estimates derived from 23 studies were 87·3% for imiquimod (95% CI 84–91%) and 84·0% for PDT (95% CI 78–90%). Only a small number of studies reported on the results of sBCC treatment with 5-fluorouracil (one), surgical excision (one) and cryotherapy (two).
Conclusions Pooled estimates from randomized and nonrandomized studies showed similar tumour-free survival at 1 year for imiquimod and PDT. The PDT tumour-free survival was higher in studies with repeated treatments. However, these results were largely derived from nonrandomized studies, and randomized studies with head-to-head comparison of imiquimod and PDT are lacking. There is a need for head-to-head comparison studies between PDT, imiquimod and other treatments with long-term follow-up to enable better recommendations for optimal sBCC treatment.